Company intelligence / Profile preview
Alar Pharmaceuticals Inc.
Taichung City, Taichung City, Taiwanalarpharm.com ↗
- Ownership
- Public · 6785
- Employees
- ~27
- Development stage
- Phase 1
01
Overview
Alar’s lead program ALA‑1000 demonstrated safety, tolerability, and sustained release over 12 weeks in opioid-dependent patients. The company recently received FDA approval to begin a Phase I trial of ALA‑3000 in treatment-resistant depression. Multiple programs are at various clinical stages targeting CNS disorders with long‑acting injectable formulations
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Long-acting injectables (LAI)Small molecules (e.g., buprenorphine, ketamine, apomorphine)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Indivior PLC – exclusive global licensing agreement for development/commercialization of buprenorphine LAI portfolio outside Greater China region ($15M upfront + milestones)
Beyond the preview
Go deeper on Alar Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alar Pharmaceuticals Inc..